Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M6620 plus avelumab and carboplatin in PARP inhibitor-resistant recurrent ovarian, primary peritoneal, or fallopian tube cancer
2018-001534-17Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Sep 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of berzosertib, avelumab and carboplatin in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Merck KGaA. Primary endpoint: Occurrence of dose-limiting toxicities. Started Sep 2018; status: completed.
02
Drugs
berzosertibavelumabcarboplatin
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2018-001534-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001534-17.